行情

RTRX

RTRX

Retrophin
NASDAQ

实时行情|Nasdaq Last Sale

11.24
+0.11
+0.99%
交易中 15:22 10/15 EDT
开盘
11.20
昨收
11.13
最高
11.52
最低
11.15
成交量
12.85万
成交额
--
52周最高
27.81
52周最低
10.87
市值
4.83亿
市盈率(TTM)
-3.2756
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RTRX 新闻

  • Retrophin: Thesis Falls Back To Sparsentan
  • Seeking Alpha - Article.15小时前
  • Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019
  • GlobeNewswire.3天前
  • Retrophin (RTRX) Investor Presentation - Slideshow
  • Seeking Alpha - Article.10/03 21:33
  • The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data
  • Benzinga.10/02 11:17

更多

所属板块

生物技术和医学研究
+1.97%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

RTRX 简况

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
展开

Webull提供Retrophin Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。